23.25
price up icon0.87%   0.20
after-market アフターアワーズ: 23.25
loading
前日終値:
$23.05
開ける:
$23.06
24時間の取引高:
917.39K
Relative Volume:
0.44
時価総額:
$3.89B
収益:
$890.53M
当期純損益:
$30.57M
株価収益率:
129.17
EPS:
0.18
ネットキャッシュフロー:
$80.53M
1週間 パフォーマンス:
+3.06%
1か月 パフォーマンス:
+3.33%
6か月 パフォーマンス:
+24.53%
1年 パフォーマンス:
+25.34%
1日の値動き範囲:
Value
$22.86
$23.39
1週間の範囲:
Value
$22.09
$23.60
52週間の値動き範囲:
Value
$13.40
$25.23

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
名前
Acadia Pharmaceuticals Inc
Name
セクター
Healthcare (1164)
Name
電話
858-558-2871
Name
住所
12830 EL CAMINO REAL, SAN DIEGO
Name
職員
654
Name
Twitter
@acadiapharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
ACAD's Discussions on Twitter

ACAD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
23.25 3.86B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-21 アップグレード Deutsche Bank Hold → Buy
2025-02-11 開始されました Deutsche Bank Hold
2025-01-03 ダウングレード Guggenheim Buy → Neutral
2024-10-10 再開されました Raymond James Mkt Perform
2024-08-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-06-27 開始されました BMO Capital Markets Outperform
2024-03-12 ダウングレード Mizuho Buy → Neutral
2024-03-12 繰り返されました Needham Buy
2024-01-30 開始されました Robert W. Baird Outperform
2024-01-24 アップグレード Needham Hold → Buy
2023-12-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-12-14 ダウングレード Deutsche Bank Buy → Hold
2023-12-13 開始されました Citigroup Buy
2023-12-12 開始されました Deutsche Bank Buy
2023-11-06 アップグレード Mizuho Neutral → Buy
2023-10-17 開始されました UBS Buy
2023-10-10 アップグレード JP Morgan Neutral → Overweight
2023-01-03 アップグレード Guggenheim Neutral → Buy
2022-11-04 ダウングレード Goldman Neutral → Sell
2022-11-01 開始されました Loop Capital Hold
2022-08-08 ダウングレード Citigroup Buy → Neutral
2022-08-05 ダウングレード Citigroup Buy → Neutral
2022-06-21 ダウングレード Jefferies Buy → Underperform
2022-06-16 アップグレード Jefferies Hold → Buy
2022-03-16 アップグレード Canaccord Genuity Hold → Buy
2022-02-09 アップグレード H.C. Wainwright Neutral → Buy
2022-01-05 アップグレード Citigroup Neutral → Buy
2021-12-21 ダウングレード Guggenheim Buy → Neutral
2021-11-01 アップグレード Guggenheim Neutral → Buy
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-06-10 開始されました Berenberg Hold
2021-04-07 ダウングレード H.C. Wainwright Buy → Neutral
2021-04-06 ダウングレード Canaccord Genuity Buy → Hold
2021-04-06 ダウングレード Goldman Buy → Neutral
2021-04-06 ダウングレード Jefferies Buy → Hold
2021-04-06 ダウングレード Mizuho Buy → Neutral
2021-04-05 ダウングレード Raymond James Outperform → Mkt Perform
2021-03-10 ダウングレード BofA Securities Buy → Neutral
2021-03-09 ダウングレード Citigroup Buy → Neutral
2021-03-09 ダウングレード Guggenheim Buy → Neutral
2021-03-09 繰り返されました H.C. Wainwright Buy
2021-03-09 ダウングレード Raymond James Strong Buy → Outperform
2021-03-09 ダウングレード Stifel Buy → Hold
2020-12-16 開始されました Mizuho Buy
2020-11-16 アップグレード Raymond James Outperform → Strong Buy
2020-08-25 開始されました Raymond James Outperform
2020-08-20 開始されました Morgan Stanley Overweight
2020-07-07 アップグレード Stifel Hold → Buy
2020-04-16 開始されました Jefferies Buy
2020-03-31 アップグレード Goldman Neutral → Buy
2020-03-06 開始されました Citigroup Buy
2019-12-16 開始されました Guggenheim Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-01 開始されました RBC Capital Mkts Outperform
2019-09-13 アップグレード SVB Leerink Mkt Perform → Outperform
2019-09-10 アップグレード Canaccord Genuity Hold → Buy
2019-07-23 繰り返されました Needham Buy
2018-12-10 開始されました Canaccord Genuity Hold
2018-09-21 アップグレード Piper Jaffray Neutral → Overweight
2018-08-09 繰り返されました Stifel Hold
2018-08-07 開始されました Stifel Hold
2018-08-06 ダウングレード Piper Jaffray Overweight → Neutral
2017-10-06 再開されました Goldman Neutral
すべてを表示

Acadia Pharmaceuticals Inc (ACAD) 最新ニュース

pulisher
Jul 25, 2025

What risks could impact ACADIA Pharmaceuticals Inc. stock performanceFree Investment Risk Control - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What drives ACADIA Pharmaceuticals Inc. stock priceHigh-yield portfolio picks - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

ACADIA Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 - BioSpace

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about ACADIA Pharmaceuticals Inc. stockPowerful profit generation - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is ACADIA Pharmaceuticals Inc. a good long term investmentTremendous return rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN

Jul 19, 2025
pulisher
Jul 17, 2025

Bank of America Securities Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Jul 17, 2025
pulisher
Jul 15, 2025

Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions - BioSpace

Jul 15, 2025
pulisher
Jul 14, 2025

What makes ACADIA Pharmaceuticals Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru

Jul 14, 2025
pulisher
Jul 10, 2025

The $12 Billion Opportunity Bolstering This Biotech Stock - Investor's Business Daily

Jul 10, 2025
pulisher
Jul 07, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com Australia

Jul 07, 2025
pulisher
Jul 03, 2025

Acadia Pharmaceuticals Rides High On Patent Wins And Strong Pipeline - Finimize

Jul 03, 2025
pulisher
Jul 03, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 03, 2025
pulisher
Jul 02, 2025

Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline - BioPharma Dive

Jul 02, 2025
pulisher
Jun 29, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Jun 29, 2025
pulisher
Jun 27, 2025

Acadia Pharmaceuticals' Stocks Undervalue Future Blockbuster Potential - Finimize

Jun 27, 2025
pulisher
Jun 26, 2025

ACAD: ACADIA Pharmaceuticals Receives Buy Rating from Needham | ACAD Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Stocks With Rising Composite Ratings: ACADIA Pharmaceuticals - Investor's Business Daily

Jun 26, 2025
pulisher
Jun 25, 2025

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers - Business Wire

Jun 25, 2025
pulisher
Jun 24, 2025

Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know - Nasdaq

Jun 23, 2025
pulisher
Jun 23, 2025

Learn to Evaluate (ACAD) using the Charts - news.stocktradersdaily.com

Jun 23, 2025
pulisher
Jun 20, 2025

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent - MSN

Jun 20, 2025
pulisher
Jun 18, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com

Jun 18, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule. - AInvest

Jun 17, 2025
pulisher
Jun 14, 2025

Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 12, 2025

US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey

Jun 11, 2025

Acadia Pharmaceuticals Inc (ACAD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):